Peptides like semaglutide are cheaper through compounding pharmacies because they exploit a loophole — same drug, fraction of the price, the FDA just hasn't caught up yet.

The compounded-semaglutide market grew rapidly in 2023-2024 as patients faced cost barriers ($1000-1300/month for branded Wegovy) and supply shortages of branded products. Compounded versions at $200-400/month were widely advertised — often with claims about "the same molecule, just cheaper because it's a loophole." That framing has become entrenched. The actual regulatory landscape is more interesting.

What compounding actually is

US compounding pharmacy is governed primarily by FDA Modernization Act section 503A (traditional compounding for individual patients) and 503B (outsourcing facilities for larger-scale preparation). Both are real regulatory pathways with specific rules — not loopholes.

Section 503A allows pharmacies to compound drugs for individual patients on a prescription basis, where the pharmacy is licensed by state boards of pharmacy and subject to USP General Chapter 797 (sterile compounding standards). The pharmacy may compound a drug that is on the FDA's drug shortage list, or where an FDA-approved version is not available in the form/strength/route the patient needs, or for specific patient-tailored reasons. Compounding from bulk active pharmaceutical ingredients (APIs) is allowed if the API is on the FDA's bulk drug substance list under section 503A.

Section 503B allows outsourcing facilities to prepare compounded drugs in larger volumes without patient-specific prescriptions, under FDA cGMP-like manufacturing oversight. The 503B facilities are registered with FDA directly and inspected more rigorously than 503A pharmacies.

The semaglutide compounding boom in 2023-2024 happened under section 503A: semaglutide was placed on the FDA drug shortage list (supply could not meet demand for Wegovy and Ozempic), which authorised compounding pharmacies to prepare semaglutide for individual prescribed patients. Most compounders sourced semaglutide API from international suppliers (China, India) and prepared sterile injectable formulations for individual prescriptions. The "loophole" framing collapses this into a single category but the actual regulatory pathway is well-defined and traceable.

Why the cheaper price

Three structural reasons:

1. No patent / development cost in the compounder's price. The branded Wegovy / Ozempic / Mounjaro / Zepbound prices reflect Novo Nordisk's and Eli Lilly's development costs, marketing, distribution margins, and patent-protected return on R&D investment. The compounder doesn't carry those costs.

2. API sourcing differs. Compounders buy semaglutide API from peptide-synthesis houses in low-cost manufacturing geographies. The API itself is much cheaper at the source than what the branded supply chain costs.

3. Lighter regulatory overhead. Section 503A compounders have lower per-batch testing requirements than FDA-registered drug manufacturers. They're inspected by state boards of pharmacy rather than by FDA directly (in most cases), and they don't need to maintain FDA submission records for each batch.

This isn't a "loophole" — it's the same regulatory framework that has existed for decades for compounding generic and specialty medications. The novel part is that a drug under active patent protection (semaglutide) became available through compounding due to the shortage classification.

Why the FDA is winding it down

As of late 2024 / early 2025, the FDA delisted semaglutide and tirzepatide from the drug shortage list (supply has caught up with demand for the branded products). When a drug comes off the shortage list, compounding pharmacies generally cannot continue to compound it under section 503A — the pathway closes. There is ongoing legal and regulatory back-and-forth about whether specific compounded preparations (different strength, different additives, dose-tailored protocols) still qualify, but the broad-volume compounded-semaglutide market is being wound down rather than expanded.

The compounded supply chain for these molecules in 2025-2026 looks substantially different from 2024:

• Patients who started on compounded versions are being moved to branded where insurance / cost allow
• Compounding pharmacies are restructuring to focus on dose-tailored or patient-specific variants that still qualify
• Some patients have moved to international supply chains outside US regulatory frameworks (which carries its own quality / legal issues)

Where the quality variance actually is

The "loophole" framing implies that compounded products are the same as branded ones, just cheaper. The actual quality picture is more variable.

Good-tier 503A compounders: USP-grade reagents, batch certificates of analysis from third-party labs, FDA inspection history without significant Form 483 findings, sterile-filtered finishing, endotoxin testing at clinically-relevant thresholds, beyond-use dating supported by stability data. Some of these pharmacies are producing genuinely high-quality compounded products.

Lower-tier 503A compounders: State-board-of-pharmacy compliance only, in-house testing only (or none), thin sterility documentation, FDA inspection findings on prior batches, beyond-use dating set by convention rather than data. Quality is variable.

International / research-chemical supply chains (separate from US compounding but often confused with it): No US regulatory oversight; quality varies dramatically; legal status varies by state and jurisdiction.

The "all compounded peptides are basically the same as branded" framing collapses this variance. The right framework asks: which specific compounding pharmacy, with what specific QC, under what specific regulatory pathway. See the compounded peptides safety critic response for the broader treatment.

Where the critic has a real point

There is a legitimate cost-access argument that the patent-protected branded prices are not aligned with the cost of producing semaglutide. The Novo Nordisk and Eli Lilly profit margins on these molecules are substantial. The compounding market existed in part because real patients couldn't afford the branded products. From a harm-reduction standpoint, compounded semaglutide is dramatically better than no semaglutide for someone who would otherwise go without therapy, and the FDA's shortage-driven authorisation of compounding was an explicit acknowledgement of this.

There is also a legitimate critique of the speed at which FDA is winding down the compounding pathway now that the shortage has resolved. The transition is creating access disruptions for patients who started on compounded versions.

Where the critic loses the thread

"Loophole" as a framing implies that compounded products bypass safety standards or that the compounders are operating outside the regulatory framework. Neither is accurate. The compounding pathway is a defined regulatory mechanism with specific rules, and the better compounders operate within those rules with substantial QC investment.

The other failure mode the framing produces: it leads patients to expect that compounded products are identical to branded ones in pharmacology and outcomes. They may be — for good compounders with verified APIs. They may not be — for compounders with inadequate QC, contaminated APIs, or inconsistent formulations. Treating "compounded" as a single category with a single quality level is the same category-collapse error that "research-only is safer than FDA-approved" makes (see that critic).

The right framing: compounded peptides occupy a defined regulatory pathway with substantial quality variance across providers. Evaluate the specific compounder (FDA inspection history, COA practices, USP grade standards) the same way you'd evaluate any pharmacy. The cost advantage is real and partly reflects the absence of patent / development costs; it does not mean the products are unsupervised or identical to branded.